Single-session strategy could transform high-risk prostate cancer care
NCT ID NCT07709338
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This trial tests a streamlined approach for men at high risk of clinically significant prostate cancer. Under one anesthesia session, doctors perform an MRI-guided biopsy, analyze the tissue immediately with rapid lab tests, and if cancer is confirmed, proceed directly to laparoscopic prostatectomy. The goal is to see if this single-stage pathway is as accurate and safe as the usual multi-step process, potentially saving time and reducing patient burden.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a streamlined diagnostic-surgical pathway combining MRI/ultrasound fusion targeted biopsy, intraoperative frozen section and rapid immunohistochemistry, and immediate laparoscopic radical prostatectomy
- What this could lead to
- If successful, this approach could allow men with high-risk prostate cancer to receive diagnosis and treatment in a single session, reducing delays and the need for a separate biopsy procedure.
- What could go wrong
- This is an early-stage study with only 150 participants, so results may not apply to all patients. The rapid pathology may not always match standard lab results, and same-session surgery carries risks like infection or bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A surgical tweak may speed bladder control recovery after prostate removal
- Smarter prostate cancer screening: a blood test that may cut unnecessary biopsies
- Glow-in-the-dark dye may help surgeons spot hidden prostate cancer cells
- Blood DNA fragments and MRI join forces to spot hidden prostate cancer
- Can an AI agent match expert urologists? a major test begins
- Pumping iron to fight cancer's hidden immune toll